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Kaposi’s sarcoma (KS) is the major AIDS-associated malignancy. It is
characterized by the proliferation of spindle cells, inflammatory infil-
trate, and aberrant angiogenesis caused by Kaposi’s sarcoma herpesvi-
rus (KSHV) infection. Small GTPase Rac1, an inflammatory signaling
mediator triggering reactive oxygen species (ROS) production by
NADPH-oxidases, is implicated in carcinogenesis and tumor angiogene-
sis.Here,weshowthatexpressionofaconstitutivelyactiveRac1 (RacCA)
driven by the -smooth muscle actin promoter in transgenic mice is
sufficient to cause KS-like tumors through mechanisms involving
ROS-driven proliferation, up-regulation of AKT signaling, and hypoxia-
inducible factor 1-–related angiogenesis. RacCA-induced tumors ex-
pressed KS phenotypic markers; displayed remarkable transcriptome
overlap with KS lesions; and were, like KS, associated with male gender.
The ROS scavenging agent N-acetyl-cysteine inhibited angiogenesis and
completely abrogated transgenic RacCA tumor formation, indicating a
causal role of ROS in tumorigenesis. Consistent with a pathogenic role in
KS, immunohistochemical analysis revealed that Rac1 is overexpressed
in KSHV spindle cells of AIDS-KS biopsies. Our results demonstrate the
direct oncogenicity of Rac1 and ROS and their contribution to a KS-like
malignantphenotype,furtherunderscoringthecarcinogenicpotentialof
oxidative stress in the context of chronic infection and inflammation.
TheydefinetheRacCAtransgenicmouseasamodelsuitableforstudying
the role of oxidative stress in the pathogenesis and therapy of KS, with
relevance to other inflammation-related malignancies. Our findings
suggest host and viral genes triggering Rac1 or ROS production as key
determinants of KS onset and potential KS chemopreventive or thera-
peutic targets.
angiogenesis  chemoprevention  hypoxia-inducible factor 1- 
reactive oxygen species (ROS)  tumorigenesis
Kaposi’s sarcoma (KS) is an angioproliferative malignancy of theskin and mucosa, which can also invade viscera in more
disseminated cases, often leading to death (1–3). KS lesions display
neovascularization, proliferation of spindle cells, and erythrocyte
extravasation (1). Classic KS affects elderly men of Mediterranean
or Eastern European Jewish ancestry. African endemic KS is
frequently observed in equatorial Africa. Iatrogenic KS is associ-
ated with immunosuppression and is frequently found in transplant
patients. Finally, epidemic KS is a major AIDS-defining malignancy
that predominantly affects HIV-infected male homosexuals (1).
Although KS incidence has decreased with the use of highly active
antiretroviral therapy (HAART), KS still leads to significant mor-
tality and morbidity in many HIV-infected patients (4). Compelling
epidemiological, pathological, and molecular evidence indicates
that infection with the -2 herpesvirus, Kaposi’s sarcoma-associated
herpesvirus (KSHV)/human herpesvirus-8, is required for KS car-
cinogenesis (2, 3). KSHV infection can lead to KS-like phenotypes
in vitro and angiogenic tumor formation in vivo. Moreover, KSHV
carries several genes that are able to induce spindle cell transfor-
mation and angiogenesis characteristic of KS, such as the viral G
protein-coupled receptor (vGPCR) (5–7), viral IL-6, K1, K12, and
viral macrophage inflammatory protein (2, 3, 8). The small GTPase
Rac1, a member of the Rho family within the Ras superfamily,
regulates a variety of cellular functions, including membrane ruf-
fling (9), cell motility (10), actin polymerization (9), cadherin-
mediated cell-cell adhesion (11), and ROS production, via members
of the phagocytic as well as nonphagocytic NADPH-oxidase
(NOX) family (12). Several studies have implicated a pathogenic
role of Rac1 in tumor development (13, 14) and in angiogenic lesion
formation by KSHV vGPCR (15). Rac-induced ROS have also
been proven to mediate Ras-induced cell transformation (16).
Rac1b, a constitutively active Rac1 splice variant expressed in some
human cancers, has been shown to promote cellular transformation
and to mediate matrix metalloproteinase-3–induced epithelial-
mesenchymal transition and genomic instability (13, 14). Seeking to
investigate the biological effects of Rac1 activation in vivo in cells
of the vascular wall, we established FVB/N transgenic mouse lines
that express constitutively active Rac1 (V12 mutant or RacCA)
under the control of the -smooth muscle actin (-SMA) promoter.
These mice showed hypertension (17) and accelerated wound
healing (18). Here, we show that as transgenic mice aged, they
developed KS lesions in a ROS-dependent manner.
Results
Transgenic Mice Expressing Constitutively Active Rac1 Develop Tu-
mors Resembling KS. We found that a significant portion of trans-
genic RacCA mice would develop discolored reddish lesions,
mainly on the tail, starting at 8 months of age (Fig. 1 A and B).
Tumorigenesis increased with age, transgene dose, and male gender
[Fig. 1F and supporting information (SI) Fig. S1]. Female trans-
genic mice developed tumors later in life (mean age  18 months).
No tumor formation was observed in WT littermates (n  79).
Histological examination of the tumors revealed many similarities
to human KS; both were characterized by excessive proliferation of
spindle cells without identifiable organized vascular structures
inside the tumors, but with slits containing red blood cells and
hemosiderin between the cells (Fig. 1 D and E). RacCA spindle cells
also stained positive for CD31, CD34, von Willebrand factor
(vWF), and -SMA, which are the characteristic phenotypic mark-
ers of KS lesions (Fig. S2). Transgene expression in the tumors was
demonstrated by a Rac1 transgene-specific RT-PCR assay (data
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not shown) and immunofluorescence double staining for Rac1.
Tumor cells coexpressed Rac1 and -SMA as expected for a RacCA
transgene driven by the -SMA promoter (Fig. 2). Moreover, Rac1-
positive tumor cells were also positive for the KS phenotypic markers
CD31 and CD34. These data are consistent with KS-like tumors being
a consequence of Rac1 transgenic expression.
Transcriptional Profiling of RacCA Tumors. Molecular signatures are
a useful way to evaluate the phenotypic identity of tumors. The KS
molecular signature was recently established by identifying 1,256 KS
genes that differentiate KS versus normal skin sample groups (19).
Similarly, we have recently established the KS-like signature of
mouse tumors induced by cells transfected with a bacterial artificial
chromosome encoding the whole KSHV infectious genome
[mECK36 tumors  KSHV-induced mouse KS-like (KSHV-mKS)
tumors] (7). To evaluate the extent to which the RacCA-induced
mouse KS-like (RacCA-mKS) tumors mimic KS and KSHV-mKS
signatures, we determined the transcriptional profile of RacCA
tumors using gene expression arrays and we sought genes from the
KS and KSHV-mKS signatures that were able to differentiate
RacCA tumors from normal mouse skin (P  0.05). Orthologs of
723 genes from the human KS signature were surveyed in the
Affymetrix mouse 430 2.0 chip. Four hundred fifty of the 723 KS
signature genes were found to be significantly up- or down-
regulated when comparing RacCA tumor versus normal skin (P 
0.05). Of those 450 genes, a total of 408 genes were similarly up- or
down-regulated in RacCA tumors and KS, and 398 of these genes
displayed similar up- or down-regulation as for KSHV-mKS tumors
(Fig. 3 A and B). Such results indicate that the RacCA tumor shares
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Fig. 2. Immunophenotype of the RacCA tumor tissue. Immunofluorescence
double staining showing colocalization of Rac1– and -SMC-actin–expressing





Fig. 1. KS-like tumorigenesis in RacCA transgenic mice. (A) Macroscopic image
of a representative tail tumor in a male RacCA/ mouse from the FVB/N strain.
(B) Tail KS-like tumor in a male RacCA/ mouse from the C57BL/6 strain. (C)
KS-like tumor on the nose of a RacCA/ mouse (FVB/N). H&E staining of tumor
tissues from an early-stage RacCA tumor (D) and a late-stage RacCA tumor (E). (F)
Tumor-free survival of homozygous male RacCA mice.
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Fig. 3. Global gene expression of RacCA tumors resem-
bles KS and KSHV-induced Kaposi-like mouse tumors. (A)
Heat map representation of 450 significantly up- or
down-regulated genes (P  0.05) from the 723 human KS
signature genes that were present on the Affymetrix
mouse 430 2.0 chip. A total of 408 genes (91%) in this
408-gene signature were equally up- or down-regulated
between RacCA-mKS and KS sample groups. Control
mouse and human SCC samples possess less than 10% of
the KS signatures. Selected up- (red) or down-regulated
(blue) genes are listed on the right. The full list of genes
is available in Table S2. (B) Distribution of KS signature.
Darkgray,genessharedbyKS,RacCA-mKS,andKSHV-mKS;
orange, genes shared by KS and RacCA-mKS; green, genes
sharedbyKSandKSHV-mKS;yellow,genesinKSonly.Gene
list is available in Table S3. (C) Up-regulation of angiogenic
gene expression in RacCA tumors compared with sur-
rounding uninvolved tissue. Bars represent mean fold
increase (triplicates  SEM) in mRNA levels quantified by
real-time quantitative RT-PCR.
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56% of the KS molecular signature and 58% of the KSHV-mKS
signature (691 genes), respectively. As a comparison, the human skin
squamous cell carcinoma (SCC) signature and a mouse SCC model
signature, which are also defined by comparison with skin, shared only
8.4% and 6.4% of the KS signatures, respectively (20, 21) (Fig. 3A). The
56% signature overlap between RacCA-mKS with KSHV-mKS and
KS suggests a major contribution of Rac activation to the KS phenotype
and further defines RacCA-mKS as an intriguing murine model for KS
derived from a single host oncogene expression.
AIDS-Associated KS Tumors Overexpress Rac1. Molecular signatures
are composed of genes critical for the malignant phenotype. Thus,
the more than 50% overlap between the transcriptional signatures
of tumors induced by RacCA with those induced by KSHV and with
human KS suggests that activation of Rac1 could play a key role in
KS. As genes involved in tumorigenesis tend to be selected for
overexpression in tumors, we determined the levels of Rac1 staining
and the latency-associated nuclear antigen (LANA) of KSHV in 4
human AIDS-KS tumor biopsies and in mECK36 tumors (Fig. 4 A and
C). We found a high level of Rac1 expression in all LANA cells of the
lesions and tumors compared with the adjacent skin that just displayed
limited patchy foci of Rac1 expression (Fig. 4 B and D).
Molecular Mechanisms of Angiogenesis Activation and Cell Prolifer-
ation in RacCA-mKS Tumors. Because angiogenic activation is a major
hallmark of KS pathogenesis, we determined by quantitative RT-
PCR the levels of angiogenic growth factors and receptors in the
tumors relative to normal skin. We found that RacCA tumors
up-regulate VEGF receptors 1 and 2 and show up-regulation of the
angiogenesis factor most up-regulated in human KS (22), angio-
poietin 2, and its receptor Tek (Fig. 3C). This pattern of expression
is indicative of paracrine and autocrine angiogenic activities in
RacCA tumors. To explore the mechanism underpinning spindle
cell proliferation, we studied cells explanted from RacCA tumors
using vascular smooth muscle cells (SMCs) from the same mice as
a control. Explanted cells lacked contact inhibition (data not
shown). Because cytokines play an important role in KS progression
and are expressed in cultured KS cells (23), we characterized
cytokine secretion. Explanted RacCA-mKS spindle cells secreted
high levels of chemocytokines and angiogenic factors, typical of
explanted human KS spindle cells, including IL-6, IL-8, TNF-,
monocyte chemoattractant protein-1 (MCP-1), macrophage in-
flammatory protein-1-alpha (MIP1), and keratinocyte-derived
chemokine (KC) (Table S1). Reduction of cytokine levels in the
media by media replacement without addition of conditioned
media factors led to cell death (data not shown), suggestive of
autocrine activities in RacCA tumor cells.
Genetic Instability in RacCA Tumors. A hallmark of most human
cancers, genomic instability has also been frequently reported in KS
(24, 25). Rac1 has been shown to induce genomic instability through
ROS (13). Additionally, as a modulator of cytoskeleton organiza-
tion, Rac1 activation could cause a defect in cytokinesis during
mitosis, leading to polyploidy and aneuploidy. We found increased
levels of DNA oxidative damage, as evidenced by the 8-oxo-dG
staining and increased phospho-H2AX (-H2AX) foci in the nuclei
of tumor cells (Fig. S3 A–F), which is suggestive of ROS-mediated
oxidative DNA damage in RacCA tumors. In RacCA tumor
primary cultures, aberrant chromosomes were frequently observed,
at a frequency varying between 5 and 10% (Fig. S3 G–I). Less than
2% of chromosome aberrance was observed in the control WT
SMCs. ModiFit FACS (Becton Dickinson) analysis showed signif-
icant presence of polyploidy and aneuploidy in RacCA tumor
primary culture (data not shown), which is also demonstrated by
manually counting chromosome spreads (Fig. S3K). p53 expression
and function are essential for avoiding proliferation of cells with
damaged genomes. Interestingly, 67% of RacCA tumor cases
examined so far showed complete loss of p53 expression, suggesting
a possible mechanism underlying RacCA-induced genetic instabil-
ity (Fig. S3J). KS tumors could have both cell-autonomous and
paracrine or reactive components (1). Although mammal cells need
more than a single oncogenic hit to become fully transformed, the
occurrence of RacCA tumors along with evidence of genetic instability
suggests that the oxidative DNA damage process initiated by RacCA
could lead to full cell transformation. To assess the presence of
transformed cells within RacCA tumors, we carried out an anchorage-
independent growth assay. RacCA tumor-explanted cells formed col-
onies in soft agar, whereas normal SMCs did not (Fig. 5G). Taken
together, our data indicate that the RacCA transgene recapitulates a
KS-like tumorigenic process involving oxidative DNA damage, leading
to genetic instability and full cellular transformation.
RacCA Tumors Display Enhanced AKT Expression and Activation. Full
transformation and tumorigenesis involve a combination of pro-
survival and proliferative activities. Rac1 is known to activate AKT
through the PI3K pathway in many cell types (26). Using gene
expression data, we showed that in the tumor tissue, the expression
of AKT1 and AKT3 are consistently 2.2- and 5.4-fold higher,
respectively, relative to intact tail tissue from WT control mice (Fig.
5A). AKT activity measured by a Meso Scale Discovery (MSD)
multispot assay demonstrated increased overall AKT phosphory-
lation in tumor tissue compared with the SMC controls and skin
(Fig. 5B). ROS are thought to affect proteins with low pKa cysteine
residues, such as protein tyrosine phosphatase (PTEN), which
functions as a tumor suppressor by negatively modulating the
PI3K-AKT signaling pathway. We examined the possibility of
inactivation of PTEN as a result of increased oxidative stress in our
RacCA mice. Immunoprecipitated PTEN activity from various
mouse tissues was compared using a malachite green assay. We
exposed PTEN to exogenous H2O2 and found that its activity
decreased in a concentration-dependent manner indicative of ox-
idative sensitivity (data not shown). We then found that PTEN
activity is reduced in all RacCA tumor tissue compared with normal
mouse tissue (Fig. 5C), with the highest reduction in activity found





Fig. 4. Rac1 is overexpressed in AIDS-KS, mECK36 (KSHV-mKS), and RacCA-mKS
tumors. Immunofluorescence detection of Rac1 and KSHV LANA expression in
AIDS-KS tumor biopsies (A), KSHV-mKS (mECK36 tumors) (C), and RacCA tumors
(D) compared with normal human skin tissue (B) and mouse skin tissue (D).











might be coupled with increased AKT activity in RacCA tumors and
may play a role in the KS tumorigenic mechanism. These results suggest
that ROS-mediated AKT activation in RacCA may contribute to
prosurvival activities leading to KS-like tumorigenesis.
Causal Role of ROS in RacCA Tumorigenesis. We further sought to
prove the role of ROS in proliferation of RacCA spindle cells.
Previously, we had shown the contribution of Rac1 and ROS to the
unchecked mitogenic activity of v-H-Ras–transformed fibroblasts
(27). RacCA mice produce excessive amounts of O2 in their SMCs
(17). Excessive O2 production is known to cause oxidative DNA
damage and genome instability (13, 28), to transform cells in culture
(29), and to potentiate tumor progression (30). To determine if
increased O2 production could be a contributor to RacCA
tumorigenicity, we measured O2 levels in the tumor (Fig. 5D). A
2-fold increase in O2 production was observed in tumor tissue
compared with normal skin tissue obtained from WT mouse tail.
In accordance with a critical role for Rac1 in ROS production, no
change in mRNA levels was observed in all major subunits of NOX,
including NOX1, NOX2, NOX4, p22PHOX, p47PHOX, p67PHOX,
NOXO1, and NOXA1, indicating that the increase in ROS pro-
duction was likely attributable to Rac1 constitutive activity and
unlikely attributable to differences in NOX levels. To establish the
role of ROS in mediating proliferation of RacCA tumor cells
further, we cultured tumor cells in the absence and presence of
N-acetyl-cysteine (NAC) or H2O2. Addition of 10 mM NAC to the
media substantially inhibited cell proliferation, whereas H2O2 fur-
ther stimulated cell growth relative to untreated tumor cells (Fig.
5E). These data suggest that ROS contribute to RacCA-induced
cell proliferation. To determine whether or not the increased AKT
activation in RacCA was linked to ROS, we determined ratios of
AKT phosphorylation in the presence and absence of NAC. As
shown in Fig. 5F, NAC treatment led to a dose-dependent reduction
in AKT phosphorylation in explanted RacCA tumor cells. KS
tumorigenicity is characterized by angiogenic activation. Rac1,
AKT, and ROS are thought to modulate VEGF angiogenesis via
hypoxia-inducible factor 1 (HIF1) (31). Fig. 5J shows that there is
an increase of HIF1- protein level in RacCA tumors that corre-
lated with increased levels of VEGF secretion by RacCA tumor
cells in vitro. As shown in Fig. 5 H and K, NAC treatment reduced
HIF-1 levels and concomitantly reduced VEGF secretion to basal
levels. The link between ROS, proliferation, AKT, and angioge-
nicity indicates that these oxidative stress mediators should be
critical for RacCA tumorigenesis. Two important pieces of evidence
indicate that this is the case. NAC completely suppressed anchor-
age-independent growth of RacCA tumor cells, and NAC delivered
in drinking water throughout the growth of transgenic animals
completely prevented the development of KS-like tumors. As
shown in Fig. 5I, RacCA transgenic mice controls (no NAC in
drinking water) developed KS-like tumors to an incidence consis-
tent with that observed in other experiments. On the other hand,
animals that received NAC in the drinking water did not develop
any detectable tumors. To determine the role of ROS in mainte-
nance of the RacCA-induced malignant phenotype, we randomized
6 tumor-bearing mice that did not receive NAC to a 3-month
placebo or NAC treatment. We found that in contrast to placebo-
receiving mice in which tail tumors almost duplicated in size,
NAC-treated animals did not show signs of further tumor growth,
suggesting that ROS are implicated in RacCA tumor cell prolifer-
ation (Fig. 5L). These results show a causal connection between
ROS and Rac1-induced KS-like tumorigenesis. Moreover, they
serve as proof of principle for the use of nontoxic antioxidants such
as NAC as potential chemopreventive agents that can be used to
block the contribution of oxidative stress to KS tumorigenesis.
Discussion
The ability of activated Rac1 to generate KS-like tumors and its








Fig. 5. Causal role of ROS in RacCA tumorigenesis. (A) Up-regulation of AKT
isoform gene expression in RacCA tumors compared with uninvolved adjacent
tissues. Bars represent mean fold increase (triplicates  SEM) in mRNA levels
quantified by real-time quantitative RT-PCR. (B) AKT phosphorylation levels (as
percentage of AKT phosphorylated/total AKT signal) in RacCA tumor compared
with smooth muscle and skin tissue, as determined by MSD (duplicate  SEM; see
Materials and Methods). (C) Activities of immunoprecipitated PTEN from various
tissues measured by release of free phosphate (see Materials and Methods)
(triplicates  SEM). (D) Lucigenin luminescence determination of (O2) produc-
tion in the tumor tissue and adjacent skin tissue compared with the tail skin tissue
from WT mice skin tissue (triplicates  SEM). (E) Effects on cell proliferation of
NAC (10 mM) or H2O2 (1 M and 100 M). Bars show percentage increase in cell
number after 24 h of incubation (triplicates  SEM). (F) Dose-dependent inhibi-
tionofAKTphosphorylation inculturedRacCAtumorcellsbyNAC(aspercentage
of AKT phosphorylated/total AKT signal) determined by MSD (duplicate  SEM).
(G) Effect of NAC (20 mM) on colony-forming ability of cultured RacCA tumor
cells. (H) Dose-dependent reduction of VEGF secretion by 24 h of NAC treatment
in cultured RacCA tumor cells. (I) Oral administration of NAC (10 mg/mL in
drinking water) prevents tumor formation in homozygous RacCA mice. (J) West-
ern blot showing increased HIF1- level in RacCA tumor tissue (T1, T2). (K) NAC
treatment (10 mM) reduced HIF1- level in cultured RacCA tumor cells after 24 h.
(L) Three months of oral administration of NAC after tumor onset (14 months)
stabilized tumor progression. Significance was established by t test: *P  0.05;
†P  0.01; ‡P  0.001; §total AKT detection did not surpass background levels.
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leading to ROS production is carcinogenic and could play a major
role in KS pathogenesis. The direct tumorigenic role of ROS in
Rac1-induced KS-like tumorigenesis and the possibility of preventing it
withnontoxicantioxidantsemphasize the importanceofoxidativestress
and its modulation for KS etiology, prevention, and therapy.
NAC inhibition of RacCA tumor formation indicates an etio-
logical role for Rac-mediated ROS production. Although RacCA
tumors were predominantly found on tails, similar histological
changes were also observed on paws, ears, and noses in separate
mice (Fig. 1C). These areas represent differentiated skin tissues, with
sparse hair coverage, a feature that might subject the skin to excessive
exposure to light (UV) and other injuries (excoriations), rendering the
exposedcellsmoresusceptible tooxidativedamage,andthereforemore
likely to experience Rac1-mediated transformation. An oxidative dam-
age etiology may also explain the gender bias of Rac1 tumorigenicity,
because it was shown that oxidative damage to mitochondrial DNA in
male mice was 4-fold higher than that in female mice because of better
antioxidant capacity of female mitochondria (32).
Our results are consistent with prior studies with a constitutively
activated Rac1 (Rac1QL) expression in endothelial cells (15). Yet,
the convergence of phenotypes of transgenes driven by endothelial
and vascular smooth muscle-specific promoters leads to interesting
questions for the pathogenesis of KS, for which the cellular origin
remains unclear (1). Our animal model points to the existence of
a potential -SMA–expressing KS spindle cell progenitor, which is
consistent with the fact that most clinical KS samples are positive
for -SMA (33). In adult animals, -SMA gene expression is highly
restricted to smooth muscle, smooth muscle-like cells, and myofibro-
blasts that are typically present in tissues subjected to mechanical stress.
Myofibroblasts become prominent under certain pathological situa-
tions such as wound healing (34). Unsupervised clustering of the
RacCA tumor transcriptome with those of different mouse cell types
placed it between SMCs and fibroblasts (Fig. S4), which is suggestive of
a myofibroblast lineage (35). It is tempting to speculate that an
-SMA–expressing cell, particularly a common endothelial-SM vascu-
lar progenitor, could be a primary cell for the RacCA-induced KS-like
tumor, and possibly also a KS progenitor cell (35).
Because it was shown that KSHV vGPCR mediates KS-like
tumorigenicity via Rac1 (15), our results are consistent with re-
ported vGPCR transgenic models of KS-like tumorigenesis (6, 7)
and with the critical role that vGPCR appears to play in KSHV-
induced carcinogenesis of KS (7, 8, 15). Our finding that Rac1 is
overexpressed in KSHV-infected spindle cells places Rac1 at the
center of KS pathogenesis. Genes that are critical for tumor biology
tend to become selected during carcinogenesis. Thus, the overex-
pression of Rac1 in the AIDS-KS lesions, together with the 56%
overlap in the transcriptome, points to a critical role for Rac1
activation in KS. The fact that all LANA cells of the lesion
overexpress Rac1 suggests that this gene is engaged in direct and
paracrine KSHV-induced angiogenesis and spindle cell prolifera-
tion. This is consistent with Rac1 playing a key role not only in the
minority of lytically infected cells that express vGPCR but in latently
infected vGPCR cells that are paracrinally stimulated by vGPCR-
expressing cells that secrete angiogenic growth factors and chemo-
kines known to mediate its biological activities via Rac1.
Our data support 3 levels of impact of Rac1 activation of ROS
in our RacCA mouse model. First, through inhibition of PTEN,
AKT-mediated survival of tumor cells is enhanced, consistent
with our prior report (27). Second, ROS-induced chromatin
oxidation and DNA damage lead to loss of gatekeeper tumor
suppressor genes like p53. Finally, ROS-mediated up-regulation
of HIF1- leads to activation of VEGF expression and angio-
genesis. The concurrence of these processes may be critical to
tumor formation in RacCA-induced KS, with variable levels.
Our results showing the carcinogenicity of constitutive Rac
activation are not only relevant to KS but to the emerging array
of malignancies in which a link with infection or inflammation
has been proven through epidemiological and experimental
evidence. They include virally induced cancers such as hepato-
cellular carcinoma induced by chronic hepatitis B virus infection,
gastric carcinoma induced by chronic Helicobacter pylori infec-
tion, and a vast array of noninfectious human cancers in which
inflammatory cells and cytokines have been shown to be integral
to the carcinogenic process. Our results show that chronic activation of
the Rac1 pathway can act as a source for carcinogenic ROS in many
human cancers. The RacCA tumor model is unique in that it is driven
solely by this pathway. Therefore, it could constitute an important tool
for seeking therapeutic and chemopreventive interventions.
The inhibition of RacCA tumorigenesis by NAC demonstrates
the causal link between oxidative stress and Rac1 tumorigenicity
and is consistent with recent findings showing the ability of NAC to
prevent myc-induced tumorigenesis by blocking ROS-induced
HIF1- stabilization (36). Our results reinforce previous studies
showing NAC inhibition of KS spindle cell angiogenesis (37). Our
results serve as proof of principle for the use nontoxic antioxidants,
such as NAC, as potential chemopreventive agents that can be used
to block the contribution of oxidative stress to tumorigenesis. Our
results showing that NAC prevented further growth of RacCA
established tumors (Fig. 5L) suggest that antioxidants could act as
tumoristatic agents and would be a valuable nontoxic adjuvant to
cytotoxic therapies. We propose that NAC preparations approved
by the U.S. Food and Drug Administration (FDA) (38), or other
prescription drugs that function by inhibiting ROS and their
production by NOX enzymes, may be effective for chemopreven-
tion and therapy of KS as well as other inflammation-related
cancers. These unique concepts warrant testing in the context of
robust preclinical and clinical studies.
Although the incidence of KS has declined since the introduction
of HAART, it remains the most common malignancy among
HIV-infected individuals in the Western world and in many devel-
oping countries, especially in Africa. Importantly, KS is still an
incurable disease (4). RacCA mice define a valuable resource for
KS research, providing a model for the development and testing of
innovative therapeutic approaches, particularly therapeutic or che-
mopreventive strategies that involve the use of selective antioxi-
dants. Our results implicating Rac1 in KS tumorigenesis and its
expression in AIDS-KS lesions define Rac1 and its downstream
pathways of oxidative stress as attractive innovative targets for both
targeted and antioxidant therapies.
Materials and Methods
Generation of RacCA Transgenic Mice. The method was described previously (18).
TransgenicmicewerescreenedbyPCR.Real-timePCRwasperformedto identify the
homozygosityandheterozygosityofthetransgenicmiceusinganABI7700Sequence
Detector (Applied Biosystems). Rodent GAPDH was used as an internal control.
Animal Treatment. Fifty age-matched, homozygous, RacCA C57BL/6 mice were
randomized to 2 identical groups on weaning. The active treatment group (n  25)
received 10 g/L NAC in their drinking water, freshly prepared every other day and
provided ad libitum. The control group (n  25) received regular drinking water
without NAC. Mice were observed for tumor development during their entire life
span. Inanotherexperiment,6maletumor-bearingRacCAmicewererandomizedto
2 matched groups (n3 each), one receiving NAC (1 g/L) in their drinking water and
the other receiving untreated water (control group). Tumor growth was measured
weekly with a caliper. One mouse in each group died attributable to non–tumor-
relatedcausesduringthestudy. It isnotunusualforC57BL/6micetobecomefrailand
occasionallydieattheageof17monthsorolder,unrelatedtoappliedtreatment.All
animal experiments were submitted to and approved by the University of Miami
Institutional Animal Care and Use Committee.
Histology, Immunohistochemistry, and Immuofluorescence. For histological
studies on mouse tissue, formalin-fixed paraffin-embedded slides were stained
with H&E, dehydrated, and mounted with Permount (Biomeda). Immunohisto-
chemistry and immunofluorescence were performed on either formalin-fixed
paraffin-embedded sections or frozen sections depending on the applicability of
the antibody. Frozen sections of human KS lesion biopsy specimens were ob-
tainedfromthetissuerepositoryof theDepartmentofPathologyandLaboratory
Medicine at the New York Presbyterian Hospital–Weill Cornell Medical Center.











Please refer to SI Materials and Methods for assay details for this and successive
method descriptions.
Cell Culture. Tumor tissue was excised under a dissecting microscope and minced.
Primary culture was maintained in DMEM (Aldrich) and 10% FBS (GIBCO) with a
half-medium change every 3 days.
Cell Proliferation Assay. Cell proliferation in the presence and absence of NAC
and H2O2 was analyzed using a Cell Proliferation Assay Kit (Chemicon) following
the manufacturer’s instructions. A total of 105 tumor cells were treated for 24 h
with 10 mM NAC or H2O2 at 100 M and 1 M in the media. Tumor cells
maintained in normal medium were used as the control.
Cytokine Measurement. Culture medium (100 L) was collected from 2-day
cultures of RacCA tumor cells and mouse SMCs. Measurement was performed using
a LINCOplex kit (LINCO Research, Inc.) following the manufacturer’s protocol.
PTEN Malachite Green Assay. PTEN was immunoprecipitated from various mouse
tissues using anti-PTEN antibody (Upstate) and protein A/G agarose beads
(PIERCE). Four hundred micrograms of tissue lysate/sample was used. The PTEN
malachite green assay (Upstate) was performed with bead-bound PTEN follow-
ing the manufacturer’s instructions. PTEN activity was measured in the amount
(picomoles) of phosphate released per 25 L reaction volume.
Phospho-AKT Assay. Levels of phospho (Ser 473)/total AKT were measured using
a Whole Cell Lysate Kit (MultiSpot Assay System) from Meso Scale Discovery. The
assay was performed according to the manufacturer’s instructions, with dupli-
cates of 20 g of total protein from mouse tissue or cell culture.
Lucigenin Assay. The lucigenin assay was performed as previously described (39).
Briefly, mouse thoracic aortas were dissected into 5-mm segments with extra
adventitial tissue removed. Aortas were equilibrated in Krebs-Hepes buffer (mil-
limolar content: NaCl, 99.01; KCl, 4.69; CaCl2, 1.87; MgSO4, 1.20; K2HPO4, 1.03;
NaHCO3, 25.0; Na-Hepes, 20.0; and glucose, 11.1) gassed with 95% O2/5% CO2 for
30 min at 37 °C. Vials with 1 mL of buffer with 100 M lucigenin were placed in
a Lumat LB9507 luminometer (Berthold Technologies). After 15 min of dark
adaptation, background readings were recorded. Aorta segments were added to
the vial. Luminescence readings were recorded at 5-sec intervals over 20 min.
Respective background readings were subtracted. Aorta segments were rinsed
with distilled H2O and placed in a 90 °C oven overnight, and dry weight was
measured. O2 production was expressed as relative light units per minute per
milligram of tissue dry weight.
Microarray. Total RNA was purified from tumor tissue, surrounding normal skin
tissue, and WT tail skin tissue using a QIAGEN RNeasy kit (Qiagen). A Mouse
Genome 430 2.0 Array (Affymetrix) was used to evaluate the expression level of
over 39,000 transcripts with 45,037 probe sets. The integrity of RNA was con-
firmed with a Bioanalyzer 2100 (Agilent Technologies). cRNA was synthesized,
labeled, and hybridized onto arrays at Duke University Microarray Facility accord-
ing to standard Affymetrix methods. Raw data intensity profiles were analyzed
using GeneSpring 7 (Agilent Technologies) to perform microarray normalization
and statistical analysis. Statistically significant genes were selected by an ANOVA
test to obtain the largest gene list that gave a false discovery rate of 1% (40).
Significantly expressed genes were clustered with GeneSpring 7 using the Pear-
son correlation method.
Statistical Analysis. A Student’s test was applied for the statistical determinations.
P  0.05 was considered significant. All experiments were repeated at least 3 times.
SI Materials and Methods. Please refer to SI Materials and Methods for further
details and description of histology, immunohistochemistry, immunofluores-
cence, chromosomalaberrationanalysis, softagarassay,flowcytometricanalysis,
RT-PCR), nested PCR, primer sequences, and PCR conditions.
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